Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium
June 22nd, 2021
Dr. Andrew Yates to Present Poster on the Company’s ART27.13 Cancer Appetite Recovery Study
Prof. Saoirse O’Sullivan to Present Poster Related to Artelo’s ART12.11 CBD Cocrystal and the Effects of CBD and TMP Coadministration in Cancer
LA JOLLA, Calif., June 22, 2021 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced that a poster featuring the ART27.13 Cancer Appetite Recovery Study (CAReS) will be presented today, June 22, at the 31st Annual International Cannabinoid Research Society (ICRS) Symposium , which is being held virtually from June 21-24, 2021. Artelo’s cannabinoid agonist, ART27.13, is being developed as a therapy for cancer patients suffering from anorexia and weight loss, which affects over 60% of later-stage cancer patients, often impacting quality of life and hastening death.
The Company also announced that a poster featuring the latest ART12.11 data will also be presented on June 23 at ICRS. ART12.11 is Artelo’s proprietary cannabidiol:tetramethylpyrazine (CBD:TMP) solid state composition, the first and only CBD cocrystal to have an issued composition of matter patent from the US Patent and Trademark Office.
“We are honored to have both posters related to our product candidates selected for presentation at the highly prestigious ICRS Symposium,” commented, Gregory Gorgas, President and Chief Executive Officer of Artelo. “As we continue to make important progress on both of these programs, we look forward to reporting stage 1 results from the CAReS trial, as well as in vivo data related to our CBD cocrystal.”
Cancer Appetite Recovery Study (“CAReS”) Poster Presentation
|Title:||Study Protocol for a Dose-Ascending, Multicenter, Randomized Controlled Phase 1/2 Trial of ART27.13 in Patients with Cancer Anorexia and Weight Loss|
|Date:||Tuesday, June 22, 2021|
|Authored by Dr. Barry Laird, coordinating investigator of CAReS; Dr. Steven Reich, Chief Medical Officer of Artelo; Dr. Andrew Yates, Chief Scientific Officer of Artelo, and presented by Dr. Yates.|
The CAReS poster forms the first of a series of publications on the Phase 1/2 study, which describes the study design and the background rationale of using ART27.13, a peripherally selective CB 1 /CB 2 receptor agonist, in this cancer population suffering from anorexia. CAReS is a two stage, randomized, double-blind, placebo-controlled clinical trial designed to investigate the utility of ART27.13 in cancer anorexia and weight loss. The first stage of the study will determine the optimal dose of ART27.13 to be used in the Phase 2 randomized study. As previously announced, the first patient was enrolled and initiated daily dosing on April 12, 2021, and the study continues to enroll. Artelo expects to report the Phase 1 results of the CAReS trial in the fourth quarter of 2021.
According to the poster’s authors, ART27.13 represents a novel mechanism-based strategy to stimulate appetite and weight gain known to arise from CB 1 receptor activation that could significantly benefit patients with cancer anorexia. For the broader community, the data that will arise from this study will help elucidate the potential of modulating the peripheral cannabinoid system in the control of appetite and weight, and inform the development strategies for trials targeting this underserved patient group.
CBD:TMP Cancer Abstract Related to Artelo’s Cocrystal
|Title:||The Effects of CBD and TMP Coadministration in Cancer|
|Date:||Wednesday, June 23, 2021|
|Presented and authored, in part, by Prof. Saoirse O’Sullivan, scientific advisor to Artelo and former Professor of Pharmacology at the University of Nottingham, UK.|
Cannabidiol (CBD) and tetramethylpyrazine (TMP) have anti-cancer properties in vitro and in vivo. However, both suffer from poor oral bioavailability. ART12.11, a cocrystal of CBD and TMP, could confer the new solid form with a more desirable pharmacokinetic profile, with the added potential for positive pharmacodynamic interactions. In this cell-based study, the effects of CBD and TMP coadministration were investigated in cancer cell lines.
The investigation found that there were synergistic and additive interactions between CBD and TMP in their ability to prevent cancer cell growth and to kill cancer cells. There was a small reduction in the anti-migratory effect of CBD when TMP was present.
The authors concluded that the positive initial studies warrant further in vivo preclinical research in animal tumor models, where an additional pharmacokinetic interaction could be expected, leading to improved drug exposure with the CBD:TMP cocrystal compared to either molecule alone.
About the International Cannabinoid Research Society
The International Cannabinoid Research Society (ICRS) is the premier global scientific association dedicated to the scientific research in all fields of the cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational cannabis. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. Interested parties may follow @ICRS_Society on Twitter and use #ICRS2021 for the latest meeting updates.
In 2018, Artelo announced a five-year commitment to sponsor the Young Investigator of the Year award at ICRS Annual Symposium. The award is a unique opportunity to identify and showcase researchers who have demonstrated dedication to endocannabinoid system research. Past recipients, Dr. Saoirse O’Sullivan, 2016 awardee and Dr. Martin Kaczocha, 2017 awardee are currently assisting Artelo with advancing its product portfolio.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio .
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.